The FDA has requested additional safety data from Eli Lilly for its oral GLP-1 medication, extending the approval timeline for what would be the first pill form of the blockbuster diabetes and weight loss drug class. For healthcare marketers who have spent 18 months watching GLP-1 demand outstrip su